The rise in installation of radiation therapy machines to treat a wide range of cancers further uplifts the probability of radiation toxicity in cancer patients. Future Market Insights (FMI), in its new study on the global Radiation Toxicity Treatment Market, foresees that the market will reach the value of US$ 5.58 Bn by the end of forecast period (2022 – 2029) and further experience a major upturn post 2029.
Request for Report Sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-10724
| Data Points | Market Insights |
| Market Value 2022 | USD 3.76 Bn |
| Market Value 2029 | USD 5.58 Bn |
| CAGR 2022-2029 | 5.8% |
| Share of Top 5 Countries | 57.4% |
| Key Players | The key players in radiation toxicity treatment market are Amgen, Jubilant Life Sciences, Siegfried Holdings , Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV |
Installed base of internal radiation therapy machines has tremendously increased over the past decade. Improving reimbursement scenario and favorable government policy framework in the field of cancer care are adding to the accessibility of radiation therapy, thereby favoring the growth of radiation toxicity treatment market.
The study suggests that notable players in Asia Pacific will continue to invest heavily in the development of new radiation therapies, in line with the increasing cancer prevalence and improving rate of diagnosis in the region.
Rising incidence of radiation toxicity in healthcare and chemicals industries continues to push the demand for effective treatment. Another important factor complementing the market growth includes recent FDA approvals to multiple orphan drugs that are proven to effectively increase the survival rate in adult and paediatric patients who are suffering from radiation sickness. These application areas continue to create growth opportunities in the radiation toxicity treatment market.
Key Takeaways – Radiation Toxicity Treatment Market Study
- Increasing adoption of colony stimulating factors such as Neulasta from Amgen will account for more than 75% of revenue share in the radiation toxicity treatment market through 2029 end.
- Attributed to high incidences of radiation toxicity due to emission of gamma radiation from positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scanners installed at hospitals and diagnostic centers, non-ionizing radiation is also set to offer lucrative opportunity to market participants.
- North America continues to lead its way in the radiation toxicity treatment market, while South Asia is foreseen to grow at a significant rate in the near future.
Speak to our Research Expert: https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-10724
Who Is Winning?
Some of the key players operating in the radiation toxicity treatment market include Amgen Inc., Partner Therapeutics, Mylan N.V., and Novartis AG. Leading players of the radiation toxicity treatment market are focusing on acquiring smaller companies to enhance their product portfolio and improve regional market positioning.
For instance, Siegfried Group announced the acquisition of drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Also, in 2018, Partner Therapeutics (PTx) acquired global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.
Scope of the Report
| Attribute | Details |
| Forecast Period | 2022-2029 |
| Historical Data Available for | 2014-2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia and Pacific, East Asia and Middle East & Africa |
| Key Countries Covered | US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, Benelux, Russia, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Thailand, Indonesia, Australia and New Zealand, Egypt, Turkey, South Africa, North Africa and GCC Countries |
| Key Segments Covered | Product, Indication, End User, Radiation and Region |
| Key Companies Profiled | • Amgen • Partner Therapeutics, Inc. • Novartis AG • Mylan NV • Coherus BioSciences Inc. • Jubilant Life Sciences • Siegfried Holdings • Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG • Recipharm AB • Mission Pharmacal Company |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Know More About the Report
Radiation toxicity treatment market, a new study from future market insights, opines on the evolution of the radiation toxicity treatment market from 2014 – 2021 and presents demand projections from 2022 – 2029 on the basis of; product type (colony stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid, and others), indication (acute radiation syndrome and chronic radiation syndrome), radiation type (ionizing radiation and non-ionizing radiation) and end user (hospitals and research & academic institutes) across seven prominent regions.